about
How to predict clinical relapse in inflammatory bowel disease patientsSerum protein profiling in patients with inflammatory bowel diseases using selective solid-phase bulk extraction, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and chemometric data analysis.Effect of eicosapentaenoic acid on E-type prostaglandin synthesis and EP4 receptor signaling in human colorectal cancer cells.New proteomic approaches for biomarker discovery in inflammatory bowel disease.Intestinal epithelial cells in inflammatory bowel diseases.N-3 fatty acids for the treatment of inflammatory bowel diseases.Eicosapentaenoic acid free fatty acid prevents and suppresses colonic neoplasia in colitis-associated colorectal cancer acting on Notch signaling and gut microbiota.The Pharmacokinetic Profile of a New Gastroresistant Capsule Preparation of Eicosapentaenoic Acid as the Free Fatty Acid.Acute Fitz-Hugh-Curtis syndrome in a man due to gonococcal infection.Mycobacterium avium subspecies paratuberculosis in the etiology of Crohn's disease, cause or epiphenomenon?Inflammation increases NOTCH1 activity via MMP9 and is counteracted by Eicosapentaenoic Acid-free fatty acid in colon cancer cells.Anticolorectal cancer activity of the omega-3 polyunsaturated fatty acid eicosapentaenoic acid.A proposed staging system and stage-specific interventions for familial adenomatous polyposisA combination of eicosapentaenoic acid-free fatty acid, epigallocatechin-3-gallate and proanthocyanidins has a strong effect on mTOR signaling in colorectal cancer cells.Isolation of stem cell populations with trophic and immunoregulatory functions from human intestinal tissues: potential for cell therapy in inflammatory bowel disease.Clinical application of faecal calprotectin in ulcerative colitis patients.Highly purified eicosapentaenoic acid as free fatty acids strongly suppresses polyps in Apc(Min/+) mice.Eicosapentaenoic acid reduces rectal polyp number and size in familial adenomatous polyposis.Polyunsaturated fatty acid pattern and fish oil treatment in inflammatory bowel disease.Pilot study: the use of sulfasalazine for the treatment of acute pouchitis.Can POSSUM accurately predict post-operative complications risk in patients with abdominal Crohn's disease?Different Cutoff Levels of Fecal Calprotectin to Predict Clinical Relapse in Ulcerative Colitis.Prepouch ileitis, myth or reality? The first case with acute abdomen.MRI Patterns in a Case of 6-Thioguanine-Related Hepatic Sinusoidal Obstruction SyndromeFecal detection of Mycobacterium avium paratuberculosis using the IS900 DNA sequence in Crohn's disease and ulcerative colitis patients and healthy subjectsIL23R, NOD2/CARD15, ATG16L1 and PHOX2B polymorphisms in a group of patients with Crohn's disease and correlation with sub-phenotypesRetention Rate, Persistence and Safety of Adalimumab in Inflammatory Bowel Disease: A Real-Life, 9-Year, Single-Center Experience in ItalyPlacebo-controlled trial of oral 5-ASA in relapse prevention of Crohn's diseaseSpread and distribution of 5-ASA colonic foam and 5-ASA enema in patients with ulcerative colitisEfficacy of 5-aminosalicylic acid enemas versus hydrocortisone enemas in ulcerative colitisScavenger effect of sulfasalazine, 5-aminosalicylic acid, and olsalazine on superoxide radical generationTopical treatment with 5-aminosalicylic in distal ulcerative colitis by using a new suppository preparation. A double-blind placebo controlled trial5-Aminosalicylic acid suppositories in the management of ulcerative colitisComparison of scintigraphy with indium-111 leukocyte scan and ultrasonography in assessment of X-ray-demonstrated lesions of Crohn's diseaseMucosal concentrations of interleukin-1 beta, interleukin-6, interleukin-8, and tumor necrosis factor-alpha in pelvic ileal pouchesRespiratory burst of circulating polymorphonuclear leukocytes and plasma elastase levels in patients with inflammatory bowel disease in remissionp-ANCA and development of pouchitis in ulcerative colitis patients after proctocolectomy and ileoanal pouch anastomosisEffects of new fish oil derivative on fatty acid phospholipid-membrane pattern in a group of Crohn's disease patientsEicosapentaenoic acid (EPA) reduces crypt cell proliferation and increases apoptosis in normal colonic mucosa in subjects with a history of colorectal adenomasSplenic granulomas in a patient with severe Crohn's disease associated with multiple extraintestinal manifestations
P50
Q26774575-CB863D9F-7EB7-4FE5-9F92-77EDD7601017Q31137034-5F00E31D-86AB-46DE-9524-E4CDFE185F13Q34041309-9C862AC0-829A-42CC-957E-215E5634ACF7Q34096526-D1E37C71-E0F6-449C-9C7B-6FE8AC008270Q34136264-029063AC-309F-4066-A21E-23418E1536BCQ34893006-7CC4D0CC-D296-4AB7-A480-08EE870C86A0Q35133949-C46C8063-C171-433F-9580-F95C4DBC72F1Q35960415-4B18E4F6-8817-4C88-89FA-855ED1B30D99Q37842613-2A1859AA-CC1A-4BB5-9864-460179A1FD19Q38256340-D13641E0-7E6A-432A-97EA-D7EED8C95BD6Q38364298-3CF1D655-5134-482C-844E-DA004CF63702Q38437209-B831A765-7BEC-49D6-85BC-E806C635A73FQ38697381-E3C3BF8B-5ABA-437C-986B-980B6DBC9BA7Q38966079-8105A534-ADCB-4F17-9D30-5219F5E2D876Q39772320-99296C33-0A98-48DA-B333-F970D7C38F42Q40605965-4D720A8A-1DB7-4EA7-A252-7390EC92E4F0Q41954579-6A2E6895-4A0A-4542-9F94-09D2F57E40B6Q43116331-9ED8DAAB-AFA5-4E21-816E-F8A72E15BADFQ43214835-2C6CA151-2D31-4139-867E-F776A99C3481Q43264490-193662B3-A74A-41D1-8830-3680F7B06079Q44083556-AAE064E3-82CD-4CAB-8411-0A834CC0C7C2Q53062014-C030EC0C-232A-48D8-9ED7-AF25A1737E98Q53359023-38DF59A7-4FE8-4FA9-A704-114161C99606Q56964717-B929D9D0-9F96-4800-908F-23583C348013Q56984269-065560C5-1CF2-467A-8E71-8E36BC5D1D82Q56986527-2556A90A-F891-4B8A-ADF3-A4461F4556CDQ58605978-988F6F77-F1BB-4417-806A-00AE55E2AFB1Q67721104-703EE923-9FB1-422B-A8A1-86BA946E7A08Q67975447-7A166AD1-87AE-43A9-B913-22D135FB7110Q68211300-E4F3DD13-822E-4943-86A0-3BEBC0D22473Q68290791-C3605A8B-33BF-4CAE-AD34-4BA9B23818F7Q68520334-4485742B-AF1B-4C52-9C16-342328282184Q69598427-4FF86F7B-3EC7-4DE6-9817-7D0C3A75A378Q70587249-50A1AB7B-90CF-4CBE-8A30-256113D9C3D6Q72048481-DE8544F3-6061-44AF-98B4-4D5C6151C60EQ72301082-0E846FBB-B83B-410C-B04B-86B3FA7774DDQ72692183-E5500244-6273-425C-B6FD-22C34BDB86DAQ72894388-956FB580-BD6E-4A16-A2E5-186D35B7DA2EQ79537453-9F0CD3B0-9016-4548-8236-9DA1871174AEQ83407056-030195D2-83CF-4BFA-B939-E81989C722AF
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Andrea Belluzzi
@ast
Andrea Belluzzi
@en
Andrea Belluzzi
@es
Andrea Belluzzi
@nl
type
label
Andrea Belluzzi
@ast
Andrea Belluzzi
@en
Andrea Belluzzi
@es
Andrea Belluzzi
@nl
prefLabel
Andrea Belluzzi
@ast
Andrea Belluzzi
@en
Andrea Belluzzi
@es
Andrea Belluzzi
@nl
P106
P1153
7004362599
P31
P496
0000-0002-9368-1014